Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European Urology Supplements  Volume 6, Issue 6, Pages 446-453 (March 2007) DOI: 10.1016/j.eursup.2007.01.014 Copyright © 2007 Terms and Conditions

Fig. 1 Use of watchful waiting and medication types in the Trans European Research into the Use of Management Policies for BPH in Primary Healthcare study [5]. Patients could have received more than one therapy. European Urology Supplements 2007 6, 446-453DOI: (10.1016/j.eursup.2007.01.014) Copyright © 2007 Terms and Conditions

Fig. 2 Cumulative progression rates to moderate and severe symptom groups in men with clinical progression from a longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for 4 yr (n=397) [20]. European Urology Supplements 2007 6, 446-453DOI: (10.1016/j.eursup.2007.01.014) Copyright © 2007 Terms and Conditions

Fig. 3 Type 1 and type 2 5α-reductase mRNA expression in normal prostate, benign prostatic hyperplasia, and prostate cancer tissues using reverse transcription-polymerase chain reaction [27]. BPH=benign prostatic hyperplasia; PCa=prostate cancer; CZ=central zone; PZ=peripheral zone; TBP=TATA-binding protein; TZ=transitional zone. European Urology Supplements 2007 6, 446-453DOI: (10.1016/j.eursup.2007.01.014) Copyright © 2007 Terms and Conditions